Login to Your Account

2012 Year in Review

Phase II Assets Gained Value, but Deals Lagged

By Marie Powers
Staff Writer

Tuesday, January 22, 2013
A Deloitte Recap LLC analysis of 2012 biopharma dealmaking activity suggested a seller's market for Phase II assets, with median up-front cash of $35 million for market rights in transactions involving at least one major territory, up from a median of $30 million during the 2007-2011 time frame.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription